Czech Republic

Targovax doses first patient in ONCOS-102 and DCVAC Phase I/II trial

Targovax, along with SOTIO, has dosed the first patient in a Phase I/II clinical trial investigating the safety and immune activation of ONCOS-102 in combination with DCVAC/PCa for the treatment of men with advanced metastatic castration-resistant prostate cancer.